Recently, Chien et al., 2020 showed that MAP1B overexpression was not only an indicator of unfavorable clinicopathological parameters but also an independent prognostic factor able to predict poor disease-specific survival and metastasis-free survival rates in patients with urothelial carcinoma of the upper tract and the bladder [86]. The gene discussed is MAP1B; the disease is urothelial carcinoma.